Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After ePCI (COBER Study)

Condition:   Coronary Heart Disease Interventions:   Drug: delayed continuous use of bivalirudin;   Drug: bivalirudin use during ePCI Sponsor:   Nanjing First Hospital, Nanjing Medical University Recruiting

Source: ClinicalTrials.gov - October 9, 2019 Category: Research Source Type: clinical trials